The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer

Seminars in Oncology

Volumn 28, Issue 1, 2001, Pages 93-105

  Los, Maartje ^a   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BATIMASTAT; CILENGITIDE; COMBRETASTATIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; REBIMASTAT; SQUALAMINE; THALIDOMIDE; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; VASCULARIZATION;

EID: 0035114055     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90047-8     Document Type: Article

References (102)

1. Tumor angiogenesis: Therapeutic implications
2. Angiogenic factors
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
5. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
6. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
7. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
8. Vascular endothelial growth factor is a secreted angiogenic mitogen
9. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
10. A heparin-binding angiogenic protein - Basic fibroblast growth factor - Is stored within basement membrane
11. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
12. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
13. Increased vascularization in mice overexpressing angiopoietin-1
14. Transforming growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor
15. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
16. ECM and cell surface proteolysis: Regulating cellular ecology
17. Requirement of vascular integrin αvβ3 for angiogenesis
18. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
19. Tumor angiogenesis: Review of current applications in tumor prognostication
20. Clinical prognostic significance of tumour angiogenesis
21. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
22. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
23. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
24. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer
25. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: Comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen
26. Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy
27. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients
28. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer
29. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer
30. Vascular attack as a therapeutic strategy for cancer
31. New strategies in anti-vascular cancer therapy
32. The implications of angiogenesis for the biology and therapy of cancer metastasis
33. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
34. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
35. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
36. Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing
37. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo
38. Thalidomide is an inhibitor of angiogenesis
39. Antitumor activity of thalidomide in refractory multiple myeloma
40. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
41. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
42. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
43. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
44. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
45. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
46. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
47. Angiogenesis: Role of calcium-mediated signal transduction
48. Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A)
49. Carboxyamidotriazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway
50. Inhibition of angiogenesis in vivo by interleukin 12
51. IL-12 deaths: Explanation and a puzzle
52. Occlusion of the hepatic artery in man
53. Organ targeting in vivo using phage display peptide libraries
54. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
55. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
56. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
57. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?
58. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
59. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
60. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
61. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470
62. Inhibition of cell motility by interferon
63. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses
64. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
65. Mechanisms to improve chemotherapy effectiveness
66. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
67. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
68. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
69. Inhibitors of angiogenesis in a clinical perspective
70. Development of angiogenesis inhibitors for cancer therapy
71. Combined effects of angiostatin and ionizing radiation in antitumour therapy
72. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
73. Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor
74. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
75. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
76. Antiangiogenic activity of prostate-specific antigen
77. A systemic approach to cancer therapy
78. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
79. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models
80. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
81. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis
82. Neoadjuvant therapy in cancer treatment
83. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for non-resectable extremity soft tissue sarcomas: A multicenter trial
84. Evidence for the involvement of endothelial cell integrin αvβ3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma
85. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy
86. Blood dissemination of colonic epithelial cells during no-touch surgery for rectosigmoid cancer
87. Metastasis: Quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine
88. Liver resection for colorectal metastases
89. Leptomeningeal metastasis after surgical resection of brain metastases
90. Antiangiogenic treatment leads to prolonged survival in mice with leptomeningeal metastases
91. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium
92. Von Hippel-Lindau disease
93. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas
94. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease
95. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis
96. Chemoprevention of head and neck and lung (pre)cancer
97. Aspirin and the risk of colorectal cancer in women
98. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2
99. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
100. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
101. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
102. Tumor-angiogenese als doelwit voor kankertherapie